
 |
|
|
|
|
|
|
|
|
|
Edward Abrahams, Ph.D. Executive Director Personalized Medicine Coalition |
|
|
|
|
|
|
|
Edward Abrahams, Ph.D., is executive director of the Personalized Medicine Coalition (PMC). Representing a broad spectrum of academic, industrial, patient, provider and payer communities, PMC seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. It has grown from its original 18 founding members in November 2004 to over 160 today. Previously he was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University. Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for the House Committee on the Interior. |
|
|
|
|
|
|
|
|
|
Kenneth A. Berlin President and Chief Executive Officer Rosetta Genomics |
|
|
|
|
|
|
|
|
|
Prior to his appointment as president and CEO of Rosetta Genomics, since July 2007, Mr. Berlin served as worldwide General Manager at cellular and molecular cancer diagnostics developer, Veridex, LLC, a Johnson & Johnson (NYSE: JNJ) company. Under his leadership the organization grew to over 100 employees, and he spearheaded the launch of three cancer diagnostic products, the acquisition of its cellular diagnostics partner, and delivered significant growth in sales as Veridex transitioned from a research and development entity to a commercial provider of oncology diagnostic products and services. During Mr. Berlin’s tenure, Veridex received numerous awards including recognition from the Cleveland Clinic and Prix Galien for the use of its innovative CellSearch® technology in the fight against cancer.
Mr. Berlin joined Johnson & Johnson in 1994 and served as corporate counsel for six years. He led and participated on the legal team that oversaw several mergers, acquisitions, divestitures and commercial transactions across Johnson & Johnson. He then held positions of increasing responsibility within Johnson & Johnson and a number of its subsidiary companies. From 2001 until 2004 he served as vice president, licensing and new business development in the pharmaceuticals group, and from 2004 until 2007 was worldwide vice president, franchise development, Ortho-Clinical Diagnostics. He has been responsible for numerous licensing and/or research collaboration deals in metabolic disease, cardiovascular disease, oncology, CNS and women’s health, including the ex-U.S. license to Millennium Pharmaceutical’s VELCADE, a first-in-class, oncology therapeutic with reported sales outside the U.S. in excess of $750 million in 2008.
|
|
|
|
|
|
|
|
|
|
|
Stephan Brand Vice President SAP AG |
|
|
|
|
|
|
|
Stephan Brand is Vice President at SAP AG and responsible for the development and Go to Market of a innovative SAP solution targeting Enterprise Knowledge Discovery. Stephan Brand is with SAP since 1996 and served in various position in sales as well as in development in Europe and Asia Pacific. In addition, he was Assistant to the executive board.
He holds a Master of Science in Industrial Engineering and Management.
|
|
|
|
|
|
|
|
Daniel Chelsky, Ph.D. Chief Scientific Officer Caprion Proteomics |
|
|
|
|
|
|
|
Dan brings to Caprion Proteomics deep industrial experience in applying the CellCarta® proteomics platform to drug target and biomarker discovery.
Prior to joining the Company, Dan was President and General Manager of BioSignal Packard Inc. (a division of Perkin Elmer), where he oversaw the development of novel technologies and reagents for drug discovery and genomics research, including the AlphaScreenTM and BRET2TM technologies and product lines. Dan also spent five years at Pharmacopeia where, as Senior Director of Biology, his team identified many lead compounds from Pharmacopeia’s million member combinatorial chemistry libraries that resulted in multiple compounds in the clinic. His previous experience also includes positions at Onyx Pharmaceuticals and the DuPont Merck Pharmaceutical Company in cancer research.
Dan received his B.Sc. from the University of California at Santa Barbara and his Ph.D. in Chemistry from the University Of Oregon Institute of Molecular Biology and was an American Cancer Society fellow at the University of California at Berkeley.
|
|
|
|
|
|
|
|
Maureen Cronin, Ph.D. Vice President, Translational Research Genomic Health, Inc. |
|
|
|
|
|
|
|
Dr. Cronin’s current position is Vice President of Translational Research at Genomic Health, Inc. There she heads a team responsible for conducting initial feasibility research for new product concepts encompassing both technical and biological aspects of each concept including laboratory processes, automation systems, and data management with bioinformatics and biostatistical analyses. All product concepts are focused on applying genomic biomarkers to provide clinically relevant molecular pathology tests for patient and physician clients. Programs focus on delivering high throughput, high-performance, innovative, first-in-class medical products in a regulated reference laboratory environment. Dr. Cronin brings 20 years of R&D experience in biotechnology companies focused on applying cutting edge technology to clinical diagnostics including ACLARA BioSciences, Protogene Laboratories and, Affymetrix where she played a key role in developing DNA microarray (GeneChipä) technology. Dr. Cronin’s Ph.D. in Molecular Pharmacology is from the University of California, San Diego and her undergraduate education from the University of California, Davis. |
|
|
|
|
|
|
|
|
|
Asif Dhar, M.D. Chief Medical Informatics Officer Deloitte LLP |
|
|
|
|
|
|
|
Dr. Dhar is Deloitte’s Chief Medical Informatics Officer. He helps clients develop innovative strategies to improve clinical outcomes and therapeutic discovery. His translational informatics work is helping clients discover new approaches to optimize clinical R&D with breakthrough information management approaches. He has been retained by numerous provider systems, Cancer Centers, Life Science companies and Governmental Agencies to define translational research programs. Dr. Dhar is also a Senior Fellow with the Deloitte Center for Health Solutions. He developed the Center’s perspective on the ROI for Personalized Medicine with the Personalized Medicine Coalition which was presented at the American Association for the Advancement of Science.
Dr. Dhar has deep functional and management experience that spans public and private sector clients. He has provided senior leadership for numerous Electronic Health Record (EHR) implementations in the US, Canada, and the UK. He has also helped design enterprise data warehousing solutions, clinical discovery applications, and quality improvement programs at large integrated delivery networks and academic medical institutions.
Dr. Dhar has a deep experience in developing clinical and research informatics programs. He is a Senior Advisor to the FDA’s Enterprise Architecture team. He also has provided biomedical informatics advisory services for the National Cancer Institute (NCI) and has served on multiple study sections for the NIH National Human Genome Research Institute. Dr. Dhar holds a Medical Degree from the University of Illinois, a Masters in Business Administration degree from the University Of Chicago Booth School Of Business, and a Bachelor in Arts degree from the University of Chicago.
|
|
|
|
|
|
|
|
|
Yael German Mayor Herzliya |
|
|
|
|
|
|
Mayor of Herzliya, Ms Yael German, is serving her third term as mayor after having won the 2009 election by a majority of the votes.
In her municipal vision she has proclaimed the city of Herzliya as a sustainable city, taking significant steps and implementing wide environmental plans; all of which were done alongside the largest investment in Israel in the fields of education, municipal infrastructures, development of cultural institutes and promotion of welfare and health.
Under her leadership, she has led public groundbreaking struggles for the environment, for public welfare and for clean government. Among which: establishing a public park at the city’s center, the fight against the placement of cellular antennas without building permits, founding a cemetery to be run by the public, with full transparency and fighting to revert the holiday apartments at the marina to be used by the public as hotels and more.
During her service, Ms German won awards and prizes, among which: the “2010 AKIM Honoree” award for her fight for AKIM wards. This is the first time in which a head of a municipality is chosen to receive the award; the 2009 Correct Government Award named after Chaim Kuberski OBM – the award was awarded by the Ministry of the Interior for responsible management of the municipality’s financial and administrative system; the ‘Women’s Network’ award – for personal leadership and city governance distinction; the education award for running the ‘Tehila’ project – a center for adult education.
German has an MBA in public leadership from the academic institution, the Interdisciplinary Center, Herzliya.
|
|
|
|
|
|
|
|
|
|
Michael A. Goldman, Ph.D. Department of Biology Prof. & Chair San Francisco State University |
|
|
|
|
|
|
Dr. Goldman did his undergraduate work in Biology at the University of Rochester and obtained a Ph.D. in evolutionary biology at Purdue University in 1981. He completed fellowships in Medical Genetics at Baylor College of Medicine in Houston and at the University of Washington in Seattle. He joined the faculty at San Francisco State University in 1988, where he is now Professor and Chair of the Department of Biology. He teaches human genetics at the graduate level, general genetics for biology majors, developmental biology for Cell & Molecular Biology majors, and an interdisciplinary course on the ethical issues in science and technology. Dr. Goldman's research is in chromatin structure and the regulation of gene expression during mammalian development. Of special interest is the relationship between chromosome structural elements called nuclear matrix attachment regions (MARs) as boundaries of functional chromatin domains, studied through molecular methods and bioinformatics. He sees the public understanding of science as a key need if science and society are to thrive, and has talked about various issues like stem cell biology for TV and radio call-in audiences. He has written Op-Ed pieces for the Los Angeles Times, the Sacramento Bee, and the San Francisco Chronicle as well a professional papers appearing in Science and Nature Genetics. Thinking that the public learns much about science and bioethics from fiction, he reviews novels addressing various aspects of genetic science and its implications, in venues like Nature, Science, Nature Genetics and the San Francisco Chronicle. |
|
|
|
|
|
|
|
|
Daniel Hershkowitz, Science and Technology Minister, Israel Government |
|
|
|
|
|
|
Rabbi Professor Daniel Hershkowitz is an Israeli politician, mathematician and rabbi. In 2009 he was elected to the Knesset as the leader of The Jewish Home, and was appointed Minister of Science and Technology.
Hershkowitz also serves as the rabbi of the Ahuza neighborhood in Haifa, as mathematics professor in the Technion – Israel Institute of Technology and as leader of The Jewish Home, for whom he is a Knesset member.
He was President of the International Linear Algebra Society.[2] He earned his B.Sc. in 1973, M.Sc. in 1976, and D.Sc. in 1982, all from the Technion. |
|
|
|
|
|
|
|
|
|
Charles Jaffe, M.D., Ph.D. CEO HL7 |
|
|
|
|
|
|
|
As the Chief Executive Officer of HL7, Dr. Jaffe serves as the organization's global ambassador, fostering relationships with key industry stakeholders. A 37-year veteran of the healthcare IT industry, Dr. Jaffe was previously the Senior Global Strategist for the Digital Health Group at Intel Corporation, Vice President of Life Sciences at SAIC, and the Director of Medical Informatics at AstraZeneca Pharmaceuticals. He completed his medical training at Johns Hopkins and Duke Universities, and was a post-doctoral fellow at the National Institutes of Health and at Georgetown University. Formerly, he was President of InforMed, an informatics consultancy for research informatics. Over the course of his career, he has been the principal investigator for more than 200 clinical trials, and has served in various leadership roles in the American Medical Informatics Association. He has been a board member on leading organizations for information technology standards, and served as the chair of a national institutional review board. Most recently, he held an appointment in the Department of Engineering at Penn State University. Dr. Jaffe has been the contributing editor for several journals and has published on a range of subjects, including clinical management, informatics deployment, and healthcare policy.
|
|
|
|
|
|
|
|
|
Eddy Karnieli, M.D. Prof. & Director, Inst. Endocrinology, Diabetes & Metabolism
Rambam Medical Center
Director, Galil Center for Telemedicine, Medical Informatics & Personalized Medicine
RB Rappaport Faculty of Medicine Technion
|
|
|
|
|
|
Professor Eddy Karnieli is a graduate of the Rappaport Faculty of Medicine at the Technion– Israel Institute of Technology in Haifa.He obtained clinical training in Internal Medicine and Endocrinology at the Rambam Medical Center and did his Post-Doctoral Fellowship in Diabetes, Obesity and Endocrinology at the National Institutes of Health in Bethesda, Maryland.
He was a visiting scholar at the University of California at San Diego and at the National Institutes of Health. He is currently the Director of the Institute of Endocrinology, Diabetes and Metabolism at the Rambam Medical Center. Professor Karnieli's main research interests are the molecular mechanisms for regulating cellular glucose uptake and transporters and their implications in diabetes, obesity and insulin resistance; Gene therapy modalities to trans-differentiate human cells toward beta-cells as a potential cure for type 1 diabetes; Medical informatics, telemedicine and personalized medicine. He has published about 70 peer reviewed papers and reviews.Professor Karnieli serves on the editorial board of several scientific journals and review boards. Professor Karnieli is a retired Colonel from the Israel Defense Forces Medical Corps and is a former Deputy Director of the Rambam Medical Center. |
|
|
|
|
|
|
|
|
Peter M. Kash President & Partner Two River Group Holdings LLC |
|
|
|
|
|
|
|
Peter Kash is co-founder and President of Riverbank Capital Securities specializing in creating and financing biopharmaceutical companies. In his more than 20 year career he has co-founded more than a dozen companies and has co-raised over $800 million in private and public financings. He has served on several private and public boards both as Chairman and Vice-Chairman. Currently he serves as Chairman of Nile Therapeutics and sits on the board of Arno Therapeutics He has traveled and lectured in over 60 countries worldwide.
Mr. Kash has worked on Wall Street for 25 years including at Shearson Lehman Hutton. From 1990-1992 he was an Associate Professor of Marketing at Polytechnic University. During 1996-2000 he was an Adjunct Professor of Entrepreneurship at the Wharton Business School. During 2000-2002 he was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo. He also served as Entrepreneur in Residence at Pace University and at Ball State University. In 2005-2006 he was a Professor at the Sy Syms School of Business. He has frequently lectured and served as a Key Note Speaker around the world, from Australia, Singapore, Egypt, to Russia and at such prestigious academic centers as: Princeton, Harvard/MIT, Technion, IDC, Recanati School of Business at Tel Aviv University and Monash University in Melbourne, Australia.
His education includes a BS in Management Science from SUNY- Binghamton and an MBA in International Banking and Finance from the Lubin School of Business at Pace University. He recently completed his Doctorate studies in Education at The Azrieli Graduate School of Yeshiva University; currently completing his Thesis. He also completed post graduate classes on Making Board’s of Directors (both Profit and Non-for Profit) More Effective at Harvard Business School.
He sits on several Non-for-profit Boards both in Israel and the United States. He has authored several books including ReStart, Make Your Own Luck and Freedom From Disease. Available in Hebrew as well.
|
|
|
|
|
|
|
|
Raphael Lehrer, Ph.D. Head of Personalized Oncology Services CollabRX |
|
|
|
|
|
Raphael Lehrer directs CollabRx ONE, our personalized oncology research service. Previously, Dr. Lehrer was the Executive Director of Strategic Alliances for Gene Logic's Drug Repositioning and Selection Business where he negotiated alliances with pharmaceutical companies to discover new therapeutic uses for their compounds that have failed in late-stage clinical trials. In earlier positions at Gene Logic, he played a key role in formulating strategy for the company; evaluating, acquiring, and integrating the preclinical CRO business; and in adding service-based offerings to Gene Logic's toxicogenomics business. Prior to joining Gene Logic, Dr. Lehrer worked at The Boston Consulting Group, where he supported top-ten pharmaceutical clients on a variety of R&D and commercial issues, including formulating licensing strategies, clinical development process design, regulatory processes, post-merger integration, and outsourcing strategies. Additionally, Dr. Lehrer was a key contributor to BCG's positioning paper on the impact of genomics on pharmaceutical R&D. Dr. Lehrer holds a B.S. degree in Physics from Yale University and a Ph.D. degree in Physics from Harvard University, where he was awarded the Maurice Goldhaber Prize for best theoretical physics student. |
|
|
|
|
|
|
|
Peter Langkafel Industry Director Healthcare EMEA SAP |
|
|
|
|
|
Peter Langkafel is Senior Business Consultant and responsible for the Healthcare within the SAP Business Consulting EMEA (Europe, Middle East, Africa). Peter Langkafel hast experience in healthcare / IT since more then 15 years. After his clinical work at a University hospital he conducted a series of IT-Projects in Medicine. He was cofounder and CEO of a small company specialized in certain IT-services in medicine. He holds a degree of “Medical Informatics” and a MBA (focused on Health Care Management). Before he came to SAP in 2005 he was head of the ”strategic business development unit “of a university hospital in Germany. |
|
|
|
|
|
|
|
|
Greg Lucier Chairman and CEO Life Technologies |
|
|
|
|
|
|
|
Greg Lucier serves as chairman and chief executive officer of Life Technologies, a global biotechnology company based in Carlsbad, California. The company is one of the largest providers of systems, biological reagents, and services supplying scientists around the world in every way that life sciences are applied. The company aims to improve the human condition by enabling basic research, accelerating drug discovery and development, and advancing scientific exploration in areas such as regenerative medicine, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Mr. Lucier is focused on preparing the company to participate in and shape the new era of medicine based on molecular technologies.
Under Mr. Lucier's leadership, the company has grown from $700 million in revenues when he took the helm in 2003 to $3.5 billion in sales today. The company has expanded to serve clients in more than 100 countries around the globe and employs more than 9,000 people. Prior to joining Life Technologies, Mr. Lucier served in a variety of executive leadership roles with General Electric Corporation, and was voted a corporate officer by that company's board of directors in 1999.
Mr. Lucier also serves as the Chairman of the Board of Trustees of the Sanford-Burnham Institute for Medical Research, as a Director for BIO, the world's largest biotechnology industry organization, and he is a member of the board of directors for Carefusion Corporation, a New York Stock Exchange listed healthcare company. He is also actively involved with the Business Roundtable in Washington D.C. Mr. Lucier is a distinguished alumnus of Pennsylvania State University, where he earned his engineering degree, and holds a masters in business administration from Harvard Business School.
|
|
|
|
|
|
|
|
Yitzhak Peterburg, M.D., Dr.P.H, M.Sc Senior Visiting Fellow, Milken Institute |
|
|
|
|
|
Yitzhak Peterburg is a Milken Institute Senior Visiting Fellow focusing on health information technology and knowledge transfer within large-scale, fragmented networks. Recently, on January 2010, has published a Milken Institute Report on the Health IT Industry in Israel and the opportunities for collaboration under the US ARRA HITECH reform.
Currently an entrepreneur and a board member of TEVA Pharmaceutical Industries Ltd, which is the world's leading generic pharmaceutical company. He was previously President and CEO of Cellcom, the leading Israeli cellular company. As the CEO of Clalit Health Services, the leading health-care provider in Israel, considered to be the second-largest HMO in the world, he led the health IT reform. Before heading Clalit, Peterburg was the Director of Soroka University Medical Center, Beer-Sheba. He holds a medical degree from Hadassah Medical School at Hebrew University of Jerusalem and is board certified in Pediatrics. He has also a doctorate in health services administration from the Columbia University School of Public Health in New York and a master's degree in information systems from the London School of Economics. He is also a Professor in the School of Business Administration at Ben-Gurion University, Beer-Sheba, and a member of the board of trustees of the Israel National Institute for Health Policy and Health Services Research. |
|
|
|
|
|
|
|
Ron Ribitzky, M.D. CEO R & D Ribitzky |
|
|
|
|
|
Dr. Ron Ribitzky is a physician executive in healthcare I.T. and life-sciences Informatics. With a track record of accelerating innovation from idea to practice; charging ahead of the technology curve, and leading multi-national cross-functional teams, Ron has a unique experience bringing together clinical insight, technology leadership, and global perspectives to drive innovation, shape strategy and execute throughout the product, solution, and service life cycle. Following 10 years in clinical practice, Ron’s informatics career developed from Sr. Programmer Analyst to Director of Applications and Research Computing at Boston Children’s Hospital; CIO at UMass Medical Center; Sr. Director Medical Sales Support, VP Prototype Development, and VP Advanced Research at Eclipsys; Sr. Healthcare Strategist and Marketing Campaign Manager for Mobile Point of Care Worldwide at Intel. Ron served as Co-Pi in ARPA National Medical Center Information Collaborative, and advisor to AT&T on the U.S. Department of Commerce/NIST National Medical Practice Knowledge Bank. Ron guided the development of the American College of Cardiology’s National Cardiovascular Data Registry, and led SAIC’ Semantic Integration Team at Kaiser Permanente’s National Clinical Information System. His academic appointments included Visiting Scientist at IBM and Weizmann Institute; Research Fellow, Medical Informatics at Harvard; Assistant Professor at UMass; and Assistant Professor, Center for Clinical Evaluation Sciences at Emory School of Public Health. He published, presented, and led workshops around the world in industry, academia, marketing, and sales events. Boards and committees include HIMSS EHR Usability Workgroup Leadership Council; CPRI Framework for Evaluating Electronic Health Records; NSF Center for Intelligent Information Retrieval; and ACSIOM, a technology transfer corporation. Ron holds a U.S. patent on component-based object-relational database infrastructure and user interface. He founded R&D Ribitzky, a healthcare I.T. and informatics firm in 1988. Ron earned his M.D. degree from the Sackler School of Medicine, Tel-Aviv University. |
|
|
|
|
|
|
|
Doina Roman, M.D. Senior Medical Director Translational Medicine Takeda Global Research & Development Center, Inc. |
|
|
|
|
|
Doina Roman, MD, is Senior Medical Director in Translational Medicine Sciences at Takeda Global Research & Development. In her role Dr. Roman leads and develops translational medicine and early clinical development strategies across multiple therapeutic areas utilizing relevant modalities such as biomarker driven development decision, modeling, imaging, emerging new technologies and statistical approaches. Before Joining Takeda Pharmaceuticals North America, Inc. Dr. Roman held several director positions at Pfizer Global Research and Development, most recently in the Clinical Development Group developing drugs in the pain and inflammation therapeutic areas. Prior to Pfizer she worked for Parke-Davis/ Warner Lambert, in the Clinical Pharmacology and Experimental Medicine Department. Dr. Roman is a graduate in Medicine from the Medical School University of Targu- Mures, Romania. Following training in Internal Medicine, she began her career in the pharmaceutical field at the Ohio State University, Clinical Pharmacology Department. In her career to date, Dr. Roman has a strong focus on translational medicine research by facilitating and improving drug development. |
|
|
|
|
|
|
|
|
David Sidransky, M.D. Chairman Champions Biotechnology |
|
|
|
|
|
|
David Sidransky, M.D. was appointed the Chairman of the Board of Directors in October, 2007. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world, in the field of oncology during the past decade, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is the Chairman of Alfacell Corporation and serves on the Board of Directors of Xenomics. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky serves as Director (2005-2008) of American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment. Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the American Association of Cancer Research. Dr. Sidransky received a B.A. from Brandeis University and M.D. from the Baylor College of Medicine. |
|
|
|
|
|
|
|
|
|
Jayson Slotnik Health Policy Specialist Foley Hoag |
|
|
|
|
|
|
Jayson Slotnik serves as Counsel in the firm’s Government Strategies practice, where he advises clients on Medicare and Medicaid coverage, as well as reimbursement and coding issues covering medical devices, diagnostic tests, drugs, and biologics. Prior to joining Foley Hoag LLP, he worked as an Associate for other nationally renowned law firms advising both payors and innovators pertaining to Medicare and Medicaid payment and coverage issues. Previously, Jayson served as the initial Director of Medicare and Medicaid Reimbursement at the Biotechnology Industry Organization (BIO), the principal trade organization for the global biotech industry, handling matters relating to insurance coverage, coding and payment of drugs and biologics. He regularly represented the industry before the Center for Medicare and Medicaid Services, as well as Congress regarding coverage and reimbursement issues. In addition, Jayson advised BIO members on business development issues and worked with the membership and affiliate groups to develop innovator friendly policies related to complex diagnostic tests and other medical therapies. Prior to law school, Jayson gained extensive private sector healthcare experience. He worked as an epidemiologist designing scientific studies demonstrating clinical effectiveness of client products. As a senior analyst for a legislative firm, he monitored Medicaid and Medicare programs for healthcare technology clients with an eye towards expanding access to clients' therapies. He started his career as a reimbursement analyst for a pharmaceutical consulting firm counseling pharmaceutical and biotechnology companies on Medicare, Medicaid and other government reimbursement policies. |
|
|
|
|
|
|
|
|
|
Lior Soussan-Gutman, Ph.D. Director Advantest/Oncotest-TEVA, Teva Pharmaceuticals |
|
|
|
|
|
|
Dr. Lior Soussan-Gutman, Director of Advantest/Oncotest-TEVA business unit in Teva Pharmaceuticals Inc. The unit provides an extended basket of services in clinical oncology, cardiovascular diseases and diabetes designed to tailor treatment to the unique characteristics of both patients and their disease.
Dr. Soussan-Gutman was the founder and CEO of Oncotest Ltd., a company offering specialized cancer diagnostic service to the oncology community based on a network of laboratories around the world.
Dr. Soussan-Gutman founded Oncotest Ltd. in 1998 and in 2003 Oncotest's activities were purchased by Teva Pharmaceutical Industries in Israel and became the Oncotest-Teva service unit, managed by Dr. Lior Soussan-Gutman. 2007 saw the extension of Oncotest-Teva's activity to additional sectors, becoming a part of ADVANTEST, with activity focusing on hereditary syndromes (risk assessment); Early Detection; Treatment Optimization; and Pharmacogenetics.
Dr. Soussan-Gutman holds a Ph.D. in Neurobiochemistry from the Tel-Aviv University and she did Post-doctorate research in molecular biology at the Weizmann Institute of Science.
|
|
|
|
|
|
|
|
|
|
Keith Strier Principal & Partner, Health Sciences & Government Practice Deloitte LLP |
|
|
|
|
|
|
Keith Strier is a Principal/Partner with Health Sciences & Government Practice of Deloitte LLP and serves in numerous roles including Co-Leader, Health Informatics and Senior Fellow in Deloitte’s Washington, DC-based healthcare think tank, Center for Health Solutions. Keith advises Ministries of Health and Multi-National Corporations alike on biomedical innovation, personalized healthcare, translational medicine and globalization themes such as medical tourism and cross-border collaboration. Keith has been a Guest Faculty at the Harvard Medical School / MIT Health Science Technology Program, lecturing on healthcare innovation, since 2002. He also serves as a Strategic Advisor to Harvard Medical School’s Center for BioMedical Informatics. Keith has been a guest speaker at many prominent US academic institutions, including UCLA’s LA BioMedical Research Institute, UC Irvine’s Healthcare MBA Program, USC’s Global BioBusiness Initiative, UC Berkeley’s BioExec Institute, Claremont’s Keck School of Applied Sciences and at the Mayo Clinic’s Inaugural Symposium on Innovation in Healthcare. Internationally, Keith has been an invited speaker at the Summit on Information Systems in Translational Research at Seoul National University in Seoul, South Korea (2008), at Peking Union Medical Center in Beijing, China (2009) and at Amgen’s 2nd annual Oncology and Hematology Conference in Istanbul, Turkey (2010). Mr. Strier has a Bachelor’s of Science in Industrial & Labor Relations with Honors from Cornell University (1993) and a Law Degree from New York University’s School of Law (1996). |
|
|
|
|
|
|
|
|
LIFE ACHIEVEMENT AWARD |
|
|
|
|
|
|
Uzia Galil President & CEO Uzia Initiatives and Management Ltd. |
|
|
|
|
|
|
|
Mr. Galil, a graduate of the Technion - Israel Institute of Technology and Purdue University in the USA was the founder of Elron Electronic Industries Ltd., and served as Chief Executive Officer of the company from 1962-1999. In 1999, Uzia Galil founded Uzia Initiatives and Management Ltd. and is presently the Chairman and Chief Executive Officer of the company, with the mission of helping regional innovations to become a global success by leveraging the experience and the global network of its management team and its partners worldwide. Uzia Galil has been awarded Honorary Doctorate degrees from Technion, The Weizman Institute of Science, Polytechnic University New York, Ben Gurion University, Solomon Bublick Prize Laureate from the Hebrew University of Jerusalem and Outstanding Electrical and Computer Engineer Award by the Purdue University, USA and the Israel Innovation Award). In 1997 he was awarded the prestigious Israel Prize for his contribution to the development of the Israel hi-tech industry.
Uzia Galil was one of the first to realize that the implementation of the "Personalized Medicine" for the benefit of the patient, requires strong corporation between the Bio-Medical and Genetic research and the advanced Computer and Bioinformatics to provide the adequate tools for the physician. This became the main purpose of the Galil Medical Center, which he founded, by leveraging interdisciplinary projects. Click here for full biography. |
|
|
|
|
|
|
|
|
COMPANY AWARD JUDGING PANEL |
|
|
|
|
|
Peter M. Kash President & Partner Two River Group Holdings LLC |
|
|
|
|
|
Peter Kash is co-founder and President of Riverbank Capital Securities specializing in creating and financing biopharmaceutical companies. In his more than 20 year career he has co-founded more than a dozen companies and has co-raised over $800 million in private and public financings. He has served on several private and public boards both as Chairman and Vice-Chairman. Currently he serves as Chairman of Nile Therapeutics and sits on the board of Arno Therapeutics He has traveled and lectured in over 60 countries worldwide. Mr. Kash has worked on Wall Street for 25 years including at Shearson Lehman Hutton. From 1990-1992 he was an Associate Professor of Marketing at Polytechnic University. During 1996-2000 he was an Adjunct Professor of Entrepreneurship at the Wharton Business School. During 2000-2002 he was a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo. He also served as Entrepreneur in Residence at Pace University and at Ball State University. In 2005-2006 he was a Professor at the Sy Syms School of Business. He has frequently lectured and served as a Key Note Speaker around the world, from Australia, Singapore, Egypt, to Russia and at such prestigious academic centers as: Princeton, Harvard/MIT, Technion, IDC, Recanati School of Business at Tel Aviv University and Monash University in Melbourne, Australia. His education includes a BS in Management Science from SUNY- Binghamton and an MBA in International Banking and Finance from the Lubin School of Business at Pace University. He recently completed his Doctorate studies in Education at The Azrieli Graduate School of Yeshiva University; currently completing his Thesis. He also completed post graduate classes on Making Board’s of Directors (both Profit and Non-for Profit) More Effective at Harvard Business School. He sits on several Non-for-profit Boards both in Israel and the United States. He has authored several books including ReStart, Make Your Own Luck and Freedom From Disease. Available in Hebrew as well.
|
|
|
|
|
|
|
|
|
David Naveh, Ph.D. Former CTO Bayer Biological Products |
|
|
|
|
|
Dr. Naveh recently retired from Bayer after 15 years as VP and CTO of Bayer Biological Products, Worldwide. Prior to Bayer, Dr. Naveh was Director of Biotech Operations at Centocor from 1988 to 1992., and previous to that held production and process development positions at Schering Plough . David Naveh participated in the development and commercialization of a number of FDA approved drugs including: Intron, Reopro, Remicaid, Myoscint, Centoxin, Kogenate, and Kogenate-FS. He currently holds seven patents including first authorship of key GM-CSF and IL-4 patents. He is a graduate of Technion in Haifa, Israel in Food Engineering(1980). He received a Ph.D. in Biochemical Engineering and an M.B.A. from the University of Minnesota, Minneapolis.He has authored over 30 peer reviewed papers and is on the editorial board of "Bioseparations." Dr. Naveh has been on BOD's of public (DSCO, BNVI) and private companies since 1995.
|
|
|
|
|
|
|
|
|
|
Shai Yarkoni, Ph.D., M.D. Director General of BioNegev |
|
|
|
|
|
|
|
Shai Yarkoni brings a unique blend of life sciences experience, combining medical practice (Israeli Board-certified Ob/Gyn) and science (cellular and molecular biology) with executive management at various biotech start-up companies and international co development ventures. Dr. Yarkoni presently has founded and currently acts as the director General of BioNegev, an Israeli Innovation cluster founded to expedite the establishment of the Israeli life science industry. Concomitantly Dr. Yarkoni heads G.A.S.R Biotechnologies, a Biotech company dedicated to restarting promising Biotech ventures that failed due to non technological reasons. G.A.S.R holds commercializing rights of projects and IP that have raised >$15M in the past. Prior to that, Dr Yarkoni served as the CEO of Target-In (fusion proteins for targeted cell suicide) and CTO of Collgard Biopharmaceuticals (small-molecule with anti fibrotic and anti angiogenic activity). In both companies Dr. Yarkoni and his teams developed the drug candidates from the academic bench to human clinical trials in USA, EU, UK and Israel.
Previously Dr. Yarkoni served for 10 years on the faculty of the Ob-Gyn dept. at the Sackler School of medicine in Tel-Aviv University, concomitantly founding and leading the Onco-Genetic service and Research Unit at the Sapir Medical Center, Israel.
Dr. Yarkoni has been involved in a number of international biotech activities, including a leading a co-development team with Boston Scientific from USA as well as Century Pharmaceuticals from India, the Steering Committee of a FP6 sponsored European Research Consortium (AMIS), as chair of the Healthcare Sector Advisory Committee to the Israel Export and international collaborations Institute, as a member of the Council of European BioRegions (CEBR) and Dr. Yarkoni holds MD and PhD degrees from the Hebrew University of Jerusalem, he published over 40 papers in peer review journals and holds 14 issued patents. |
|
|
|
|
PMWC ISRAEL PLANNING COMMITTEE |
|
|
|
|
|
Amos Barzilay Venture Consultant Walden International |
|
|
|
|
|
Until recently, Dr. Barzilay was the interim CEO of CollabRx, a biotechnology company whose goal is to help oncologists develop customized therapies for cancer patients who are unresponsive to standard treatments. Dr. Barzilay is a Venture Consultant and was a General Partner with Walden International, a global Venture Capital firm with over $2 billion under management. At Walden Dr. Barzilay led several investments in innovative software companies and served on their boards. Prior to joining Walden Dr. Barzilay was Vice President & General Manager, Content and Supplier Solutions in Commerce One. Dr. Barzilay joined Commerce One as part of Commerce One's acquisition of Mergent Systems in January 2000. Dr. Barzilay was a co-founder, chairman, and CEO of Mergent Systems, a business-to-business e-commerce infrastructure start-up. Prior to Mergent, Dr. Barzilay held a variety of senior management positions including General Manager of C*ATS, senior marketing executive at Informix and CEO at Syntelligence Systems. Prior to Syntelligence, Dr. Barzilay was an AI researcher at Xerox Parc. Dr. Barzilay has an engineering degree from the Technion in Israel and an M.B.A. and Ph.D. degree from the University of Pittsburgh. |
|
|
|
|
|
|
|
|
Tal Behar Executive Director Silicom Ventures |
|
|
|
|
|
Tal Behar is the executive director of Silicom Ventures since January 2001. Most recently, Tal founded the Personalized Medicine World Conference (PMWC) with the mission to enable a platform which aids in the accelerated adoption of Personalized Medicine on a global-scale. Tal has extensive experience in event organization and production. Under her leadership Silicom Ventures launched over 160 high technology events located in Silicon Valley and abroad. Tal was instrumental in helping Silicom Ventures grow from 25 to over 250 members. Tal's duties as Silicom Ventures' Executive Director involve marketing, business development, and operations - often, she is the voice of Silicom Ventures to some of the most prominent players in the investment, business and political worlds. Prior to Silicom Ventures Tal was a Law student at Tel Aviv University in Israel. Previously she was a senior officer in the IDF for over three years.
|
|
|
|
|
|
|
|
|
|
|
BOOT CAMP SPEAKERS |
|
|
|
|
|
Joseph Bach Partner Nixon Peabody |
|
|
|
|
|
Mr. Bach has more than a decade of legal experience in all aspects of intellectual property law, including patent prosecution and litigation. Joseph has developed methodologies for, and counsels clients on, efficiently building and managing effective patent portfolios. Joseph has successfully handled and managed cases in a broad range of technologies and has litigation experience before the International Trade Commission and federal courts. Joseph was formerly Senior Director of Intellectual Property at Applied Materials, where he was responsible for all aspects of the company's intellectual property internationally. He hold a law degree from the Duke University School of Law and a B.S. Engineering and Applied Science from California Institute of Technology (Caltech). |
|
|
|
|
|
|
|
|
Amos Barzilay Venture Consultant Walden International |
|
|
|
|
|
Until recently, Dr. Barzilay was the interim CEO of CollabRx, a biotechnology company whose goal is to help oncologists develop customized therapies for cancer patients who are unresponsive to standard treatments. Dr. Barzilay is a Venture Consultant and was a General Partner with Walden International, a global Venture Capital firm with over $2 billion under management. At Walden Dr. Barzilay led several investments in innovative software companies and served on their boards. Prior to joining Walden Dr. Barzilay was Vice President & General Manager, Content and Supplier Solutions in Commerce One. Dr. Barzilay joined Commerce One as part of Commerce One's acquisition of Mergent Systems in January 2000. Dr. Barzilay was a co-founder, chairman, and CEO of Mergent Systems, a business-to-business e-commerce infrastructure start-up. Prior to Mergent, Dr. Barzilay held a variety of senior management positions including General Manager of C*ATS, senior marketing executive at Informix and CEO at Syntelligence Systems. Prior to Syntelligence, Dr. Barzilay was an AI researcher at Xerox Parc. Dr. Barzilay has an engineering degree from the Technion in Israel and an M.B.A. and Ph.D. degree from the University of Pittsburgh.
|
|
|
|
|
|
|
|
|
Steve Blank Lecturer UC Berkeley, Stanford University |
|
|
|
|
|
Steve Blank is a retired serial entrepreneur and has been a founder or participant in eight Silicon Valley startups since 1978. After he retired, he wrote a book about building early stage companies. He's moved from being an entrepreneur to teaching entrepreneurship to both undergraduate and graduate students at U.C. Berkeley, Stanford University and the Columbia University/Berkeley Joint Executive MBA program. The “Customer Development” model that he developed in his book is one of the core themes for these classes. In 2009 he was awarded the Stanford University Undergraduate Teaching Award in the department of Management Science and Engineering.
|
|
|
|
|
|
|
|
|
Bill Joos Principal Go To Market Consulting |
|
|
|
|
|
|
|
|
|
Bill Joos is the principal of "Go To Market Consulting", based in Palo Alto, California. He works with early stage startups, venture capital firms and their portfolio clients.
He spent nearly 7 years as the VP of Entrepreneur Development at Garage Technology Ventures, an early stage venture capital firm that he co-founded along with Guy Kawasaki. His reputation at Garage was that he provided their clients with effective, hands-on, action-oriented strategic and tactical mentoring and coaching.
Bill has worked with literally hundreds of early-to-mid stage high technology startups and helped them polish and clarify their messages and refine their fund-raising and customer presentations; but his contributions to them extended well beyond being a "Pitch Doctor". He has mentored and coached them in go to market strategies, revenue and pricing optimization, business alliances, business development, partnerships, and marketing.
Over 20,000 entrepreneurs worldwide have attended conferences where Bill has been a featured keynote speaker on various entrepreneurial topics.
He has also held sales and marketing positions with a variety of companies, including IBM and as the Sales VP at the software division of Apple Computer. |
|
|
|
|
|
|
|
|
|
|
|
Noga Kap Managing Director BRM Group |
|
|
|
|
|
|
|
Bringing over twenty years of hands-on experience in sales, finance and management in the high-tech industry, Ms. Noga Kap is responsible for all seed and early-stage investments in BRM Hi-Tech.
Prior to joining BRM, Noga was General Partner at Walden Israel Venture Capital from 2000-2008. Before joining Walden, she founded the first European subsidiary for MINT Technologies, a leading provider of intelligent middleware solutions for application integration in the financial services industry, leading the company to become a leader in the EAI market, including the acquisition of SunGard Data Systems Inc. (NYSE:SDS). Prior to MINT, Noga held several managerial Operations positions in telecom service companies in Israel and abroad, notably Consortium International and Koor Communications.
Currently Noga sits on the board of MediaBoost and Mo'Minis and until recently was on the Board of Directors for a number of technology companies, including Mellanox (NASDAQ:MLNX), Zend Technologies, SintecMedia, Safend, Amimon, EPOS and Universal Ad. Noga holds a B.Sc. in Economics and Psychology from Tel Aviv University and an MBA from Washington University.
|
|
|
|
|
|
|
|
Dalia Megiddo, M.D. Managing Partner 7 Health Ventures |
|
|
|
|
|
Before joining 7 Health Ventures Dr. Megiddo was the managing partner in InnoMed Ventures, one of the leading Israeli healthcare venture funds since 2000.
Dr Megiddo has been involved in the Life Science Venture Capital Industry since 1999 and is well recognized as one of the leaders in the healthcare investment community both in Israel and internationally. She is a frequent speaker at local and international meetings and served as a board member of public companies: Given Imaging (NASDAQ-GIVN) and Elron (NASDAQ-ELRN), as well as private companies (Glucon, Impliant, Chiasma, Notal Vision and Barnev).
Dr Megiddo holds an MBA from Kellogg- Recanti School of Business, and teaches at various entrepreneurial programs in Israeli universities. She completed her medical studies at the Hebrew University’s Hadassah Medical School in Jerusalem in 1978.
After spending a few years as a faculty member in the Family Medicine department at the Hebrew University in Jerusalem, Dr. Megiddo founded and sold two successful businesses in the medical field: The Journal Club - Israel’s leading provider of Continuing Medical Education for physicians, and Academia Medica – a medical multimedia developer and worldwide distributor for Continuing Medical Education programs for physicians. |
|
|
|
|
|
|
|
Benny Schnaider Co-Founder & former CEO Qumranet (acquired by Redhat) |
|
|
|
|
|
Benny Schnaider was Qumranet's CEO and a Co-Founder. The company was acquired by Redhat in 2008.
Benny was CEO and Co-Founder of PentaCom Ltd. a provider of networking products which was acquired by Cisco in 2000. Benny also co-founded and served on the Board of Directors for P-Cube, a developer of IP service control platforms, which was acquired by Cisco in 2004. Over the past 30 years, Benny has held senior management, engineering and strategic roles at many Silicon-Valley based companies including Cisco Systems, Amdahl/Fujitsu, Hitachi, IDT, Sun Microsystems and 3Com. Benny holds a Masters degree in Engineering Management from Santa Clara University, and a B.Sc in Computer Engineering from the Technion (Israel Institute of technology).
|
|
|
|
|
|
|
|
|
Benny Zeevi, M.D. Managing General Partner DFJ Tamir Fishman Ventures |
|
|
|
|
|
Dr. Benny Zeevi is a Managing General Partner in DFJ Tamir Fishman Ventures and leads the fund Life Science and Cleantech investments. Dr. Zeevi is a physician specialized in interventional pediatric cardiology. Prior to joining DFJ TFV in 2003, Dr. Zeevi was the Vice President Business Development & Medical Director of Card Guard AG since 1998. Dr. Zeevi is very active in the Israel life science industry and is the Chairman of the life science committee of Israel Venture Association and served on the board of the Israeli Life Science Industry Organization. Dr. Zeevi is the Founder and Co Director of an Executive Program for Biotechnology and Medical Device Entrepreneurs and Managers, based on International faculty, at The Faculty of Management of Tel-Aviv University. He has an extensive background in product development, marketing and strategy formulations in Life Science technology companies. Dr. Zeevi served, among other capacities, as a professional advisor to several life science companies and venture capital funds while he was still practicing medicine. Dr. Zeevi is a certified Pediatric Cardiologist. From 1990-1998 he was Director of Pediatric Catheterization Unit, Schneider Children's Medical Center in Israel. Dr. Zeevi was a fellow and a visiting Professor and part-time clinical staff at the Children's Hospital, Harvard Medical School in Boston. His contributions have been acknowledged in 1993, when he received the Liberman prize for significant contributions to the evaluation and treatment of children with congenital heart disease. |
|
|
|
|
WEIZMANN INSTITUTE SPEAKERS |
|
|
|
|
|
Israel Bar-Joseph, Ph.D. Vice President for Resource Development &
Dean of Educational Activities
The Weizmann Institute of Science |
|
|
|
|
|
Prof. Israel Bar-Joseph was born in Israel in 1953. He graduated with a B.Sc. in Physics from Tel Aviv University and an M.Sc. and Ph.D. in Physics from the Weizmann Institute of Science, with honors. He is the recipient of the 1985 Kennedy Prize, the 1989 Alon Fellowship and the 1994 Levinson Prize. In 1989, he joined the Weizmann Institute of Science, where he is now a professor in the Physics Faculty. He has served in a variety of scientific management positions at the Institute: Director of the Braun Center for Submicron Research, Head of the Physics Services, Head of the Condensed Matter Physics Department and Director of the Maurice and Gabriela Goldschleger Center for Nanophysics. Since December 2006, he is the Weizmann Institute’s Vice President for Resource Development, and since 2007 – Dean of Educational Activities. From 2001 to 2006, he served as a member of the board of Yeda, the Weizmann Institute’s technology transfer arm. He was a visiting professor at EPFL in Lausanne, Switzerland, at Columbia University in New York, USA, and at Ecole Normale Superieure in Paris, France. At the Weizmann Institute, he is the incumbent of the Jane and Otto Morningstar Professorial Chair in Physics.
Prof. Bar-Joseph’s main research fields are nanophysics and electro-optics of semiconductors. He has published over 100 papers in scientific journals and served as a member of the editorial boards of leading journals such as Physical Review Letters and Semiconductor Science and Technology. His public activities span environmental and educational issues. He was a member and chairman of the board of the Society for the Protection of Nature in Israel and a member of several government committees on science education. He is married to Revital and is the father of three boys: Asaf, Omer and Amos.
|
|
|
|
|
|
|
|
|
Amir Naiberg CEO YEDA Research and Development Co. Ltd. |
|
|
|
|
|
Amir Naiberg holds an LL.M. degree from the University of Connecticut School of Law and an LL.B. degree from the Hebrew University of Jerusalem. Prior to his appointment as Yeda's CEO, Mr. Naiberg served as Yeda's General Counsel for six years. Before joining Yeda, Mr. Naiberg worked for a private law firm specializing in intellectual property, privacy and cyberspace law.
|
|
|
|
|
|
|
|
|
Eran Segal, Ph.D. Department of Molecular Cell Biology The Weizmann Institute of Science |
|
|
|
|
|
Dr. Eran Segal’s group develops computational models aimed at understanding how molecular components interact to carry out complex biological functions. To achieve this goal, Dr. Segal integrates heterogeneous types of genomic data into unified statistical models, based on the language of probabilistic graphical models. Dr. Segal’s research currently focuses on three areas: the development of transcription models; understanding microRNA - RNA interactions; and the development of sequence-based models that explain the positioning of nucleosomes along the DNA strand.
Nucleosomes are those fundamental units of chromatin, which hang bead-like along the DNA strand, separated by free areas of about 20 base pairs. The nucleosome packaging inhibits access to
many proteins, including those responsible for DNA replication, transcription, and the repair of damaged DNA. These processes are restricted to the brief nucleosome free areas.
Using probabilistic models for gene regulation networks, and computer algorithms, Dr. Segal and his colleagues demonstrated that the DNA sequence contains instructions that determine the location of the nucleosomes along the DNA strand, and also deciphered the code and characterized it to such a degree that has enabled them to determine the location of a large number of nucleosomes in yeast cells. Their findings were published in Nature, in a paper that was rated “exceptional” by the Faculty of 1000, an online research service that evaluates and highlights the most interesting papers published in the biological sciences. Dr Segal’s discoveries were also published in the July 25, 2006 edition of the New York Times.
Born in Tel Aviv in 1973, Dr. Eran Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a Ph.D. in Computer Science and Genetics in 2004, from Stanford University. Three of his thesis publications received the best paper and best student paper awards at leading international bioinformatics conferences. In 2005, after completing postdoctoral research at Rockefeller University, New York, Dr. Segal joined the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science. Dr. Segal was recently awarded the 2007 Overton prize by the International Society for Bioinformatics (ISCB), an award that is given to one scientist a year, in the early to mid career stage, for outstanding accomplishments in the field of computational biology.
|
|
|
|
|
|